

# Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

NCT06799247

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Cartesian Therapeutics
Enrollment	100 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Patient must be at least 18 years of age.
- Patient must have generalized myasthenia gravis (gMG), Myasthenia Gravis Foundation of America (MGFA) clinical classification grades 2-4 at the time of Sscreening.
- MG-Activities of Daily Living (MG ADL) total score e 6.
- Concomitant immunosuppressive drugs must be deemed necessary by the investigator. The dose must be stable for a minimum of 8 weeks prior to Baseline visit.
- If a patient is using corticosteroids, the daily dose should not exceed 40 mg/day of prednisone equivalent. The dose must have been stable for a minimum of 8 weeks prior to Baseline visit.

... and 4 more (see full listing online)

### Exclusion (28)

- Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient.
- Diagnosis of gMG within 12 months of screening.
- No history of systemic treatment for gMG other than acetylcholine esterase inhibitors.
- Diagnosis of a neuromuscular disease other than gMG.
- Patient is pregnant or lactating.

... and 23 more (see full listing online)

## Locations (34 total)

---

A40, Tucson, Arizona, United States  
A13, Carlsbad, California, United States  
A46, Los Angeles, California, United States  
... and 31 more locations

---

<https://clinicaltrials.gov/study/NCT06799247>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.